|06-22-2018 08:17 AM CET - Advertising, Media Consulting, Marketing Research||
Dengue Fever - Pipeline Review, H1 2018
Press release from: HTF Market Intelligence Consulting Pvt. Ltd.
HTF Market Report released a new research document of 158 pages on industry titled as 'Dengue Fever - Pipeline Review, H1 2018' with detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes important players/vendors such as GeneSegues , GlaxoSmithKline , Globavir Biosciences , Immunotope etc The report will help you gain market insights, future trends and growth prospects for forecast period.
Request a sample report @ www.htfmarketreport.com/sample-report/1226081-dengue-feve...
HTF’s latest Pharmaceutical and Healthcare disease pipeline guide Dengue Fever - Pipeline Review, H1 2018, provides an overview of the Dengue Fever (Infectious Disease) pipeline landscape.
Dengue is a mosquito borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from nose, gums, or under skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. Treatment includes use of analgesics, fluid replacement therapy and healthy life style.
HTF’s Pharmaceutical and Healthcare latest pipeline guide Dengue Fever - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Dengue Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dengue Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 24, 17 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3, 13 and 12 molecules, respectively.
Dengue Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from HTF’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dengue Fever (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Dengue Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dengue Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dengue Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dengue Fever (Infectious Disease)
Buy this report @ www.htfmarketreport.com/buy-now?format=1&report=1226081
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dengue Fever (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dengue Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
Biological Mimetics Inc
Chugai Pharmaceutical Co Ltd
Emergex Vaccines Ltd
Ennaid Therapeutics LLC
Globavir Biosciences Inc
Inovio Pharmaceuticals Inc
Johnson & Johnson
Merck & Co Inc
NovaTarg Therapeutics Inc
Panacea Biotec Ltd
Plex Pharmaceuticals Inc
Shionogi & Co Ltd
SIGA Technologies Inc
Sun Pharma Advanced Research Company Ltd
Takeda Pharmaceutical Co Ltd
VLP Therapeutics LLC
Get Customization in the Report, Enquire Now @ www.htfmarketreport.com/enquiry-before-buy/1226081-dengue...
Dengue Fever - Overview 6
Dengue Fever - Therapeutics Development 7
Dengue Fever - Therapeutics Assessment 18
Dengue Fever - Companies Involved in Therapeutics Development 26
Dengue Fever - Drug Profiles 38
Dengue Fever - Dormant Projects 132
Dengue Fever - Discontinued Products 137
Dengue Fever - Product Development Milestones 138
Appendix 149List of Tables
Number of Products under Development for Dengue Fever, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
View Detailed Table of Content @ www.htfmarketreport.com/reports/1226081-dengue-fever-pipe...
It's vital you keep your market knowledge up to date. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization accordingly.
HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”.
Contact US :
Craig Francis (PR & Marketing Manager)
HTF Market Intelligence Consulting Private Limited
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA – 08837
Phone: +1 (206) 317 1218
Connect with us at
This release was published on openPR.
News-ID: 1093191 • Views: 192More releases